- Home
- RVSB vs ANVS Comparison
RVSB vs ANVS Comparison
Compare RVSB & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSB | ANVS |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 69.1M |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RVSB | ANVS |
|---|---|---|
| Price | $5.49 | $2.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $13.50 |
| AVG Volume (30 Days) | 30.2K | ★ 923.2K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $1.54 |
| 52 Week High | $6.15 | $5.50 |
Technical Indicators
Market Signals| Indicator | RVSB | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 47.55 |
| Support Level | $4.92 | $1.86 |
| Resistance Level | $5.56 | $2.57 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 77.23 | 41.15 |
Price Performance
Historical ComparisonAbout RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.